Differences in gene expression profile between vocal cord Leukoplakia and normal larynx mucosa by gene chip

Jianhua Peng, He Li, Jun Chen, Xianming Wu, Tao Jiang and Xiaoyun Chen

Abstract

Background: Long non-coding RNAs (lncRNAs) play an important role in tumorigenesis. Vocal cord leukoplakia is a precancerous lesion in otolaryngological practice. Till now, the expression patterns and functions of lncRNAs in vocal cord leukoplakia have not been well understood. In this study, we used microarrays to investigate the aberrantly expressed lncRNAs and mRNAs in vocal cord leukoplakia and adjacent non-neoplastic tissues.

Methods: Gene Ontology and pathway analyses were performed to determine the significant function and pathways of the differentially expressed mRNAs. qRT-PCR was performed to further validate the expression of selected lncRNAs and mRNAs in vocal cord leukoplakia.

Results: Our study identified 170 differentially expressed lncRNAs and 99 differentially expressed mRNAs, including 142 up-regulated lncRNAs and 28 down-regulated lncRNAs, and 54 up-regulated mRNAs and 45 down-regulated mRNAs. Among these, XLOC_000605 and DLX6-AS1 were the most aberrantly expressed lncRNAs. Furthermore, we identified an antisense IncRNA (LOC100506801), an enhancer-like IncRNA (AK057351) and three long intergenic noncoding RNAs including XLOC_008001, XLOC_011989 and XLOC_007341.

Conclusions: Our results revealed that many lncRNAs were differentially expressed between vocal cord leukoplakia tissues and normal tissue, suggesting that they may play a key role in vocal cord leukoplakia tumorigenesis.

Keywords: Vocal cord leukoplakia, Long non-coding RNAs, Gene chip, Microarray

Background

Leukoplakia is a term to describe a mucosal white patch or plaque that cannot be easily scraped off. Vocal cord leukoplakia is a common precancerous lesion in otolaryngological practice. The annual incidence in the United States is estimated to be 10.2/100000 in males and 2.1/100000 in females. A comprehensive meta-analysis of laryngeal leukoplakia by Isenberg et al. revealed that 8.2% cases underwent malignant transformation during a follow-up period that ranged from 1 to 233 months between various studies. Overall 3.7% nondysplastic, 10.1% mild to moderate dysplastic and 18.1% severely dysplastic cases underwent malignant change [1]. Studies have identified smoking and alcohol as major causes and there is also sufficient evidence implicating gastroesophageal reflux and human papilloma virus in the pathogenesis of the disease [2]. Vocal cord leukoplakia is clinically significant due to the potential for malignant transformation. A variety of proliferation markers, cyclin kinases, oncoproteins, tumor suppressors, mutations microsatellite loss of heterozygosity (LOH), nuclear image parameters and DNA ploidy have been investigated in laryngeal dysplasias, which has provided insight into the molecular mechanism of carcinogenesis [3–5]. Bartlett et al. also identified several genes including IGF-1, EPDR1, MMP-2, S100A4 which were differentially expressed between vocal cord leukoplakia and normal vocal cord tissues [6]. Despite many investigations, the exact mechanism of vocal cord leukoplakia tumorigenesis remains unclear.

Recently, a new class of noncoding RNAs, designated long noncoding RNAs (lncRNAs), was found to be
frequently dysregulated in various diseases. LncRNAs are transcript RNA molecules longer than 200 nucleotides that do not encode a protein and reside in the nucleus or cytoplasm [7]. Aberrant expression of IncRNAs can lead to abnormalities in gene expression and tumorigenesis. The altered expressions of IncRNAs are a feature of many types of cancers and have been shown to promote the development, invasion, and metastasis of tumors by a variety of mechanisms [8]. Studies have shown that IncRNAs play an important role in larynx squamous cell carcinoma (LSCC) progression. Shen et al. reported that AC026166.2–001 was the most down-regulated IncRNA and RP11-169D4.1–001 was the most up-regulated IncRNA in LSCC tissue compared to normal laryngeal tissue [9]. Some other IncRNAs also have been reported to be correlated with LSCC tumorigenesis and progression [10–14]. However, the role of IncRNAs in vocal cord leukoplakia tumorigenesis remains unclear.

In this study, we used gene microarray analysis to measure the expression patterns of IncRNAs and mRNAs in vocal cord leukoplakia samples and compared them with the corresponding patterns in adjacent nontumorous tissue (NT) samples. Several of the differentially expressed IncRNAs were evaluated by SYBR RT-PCR in 100 pairs of tissue samples. Our results suggest that the dysregulation of IncRNAs might play an important role in vocal cord leukoplakia tumorigenesis.

Methods

Patients samples

Vocal cord leukoplakia samples and control normal vocal cord mucosal samples were collected from 103 patients of the Department of Otolaryngology, First Affiliated Hospital of Wenzhou Medical University, China, from June 2015 to June 2016. Three samples were used for microarray analysis of IncRNAs and 100 were used for quantitative PCR (Q-PCR) validation. The clinical characteristics of patients with leukoplakia vs normal tissue (control) used in gene microarray were shown in Table 1. The diagnosis of vocal cord leukoplakia was based on clinical history and white light laryngoscopy findings and further confirmed by histopathologic diagnosis of parakeratosis and mild to severe dysplasia. The vocal cord leukoplakia and matched normal vocal cord mucosal samples were snap-frozen in liquid nitrogen immediately after resection. This study was approved by the Institutional Ethics Review Board of the First Affiliated Hospital of Wenzhou Medical University, and all patients provided written informed consent for this study.

RNA extraction

Vocal cord leukoplakia samples and normal vocal cord mucosal samples were obtained by biopsy under white light laryngoscopy. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s protocol. The integrity of the RNA was assessed by electrophoresis on a denaturing agarose gel. A NanoDrop ND-1000 spectrophotometer was used for the accurate measurement of RNA concentration (OD260), protein contamination (OD 260/OD 280 ratio), and organic compound contamination (OD 260/OD 230 ratio).

Microarray and computational analysis

For microarray analysis, an Agilrent Array platform (Agilent Technologies, Santa Clara, CA, USA) was employed. The microarray analysis was performed as described by our colleagues [15]. Briefly, sample preparation and microarray hybridization were performed based on the manufacturer’s standard protocols with minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA by using an mRNA-ONLY Eukaryotic mRNA Isolation Kit (Epitect Bio-technologies, USA). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3’ bias by using a random priming method. The labeled cRNAs were hybridized onto a Human IncRNA Array v3.0 (8 × 60 K; Arraystar), which was designed for 30,586 IncRNAs and 26,109 coding transcripts. The IncRNAs were carefully constructed using the most highly respected public transcriptome databases (RefSeq, UCSC Known Genes, GENCODE, etc.) as well as landmark publications. Each transcript was accurately identified by a specific exon or splice junction probe. Positive probes for housekeeping genes and negative probes were also printed onto the array for hybridization quality control. After washing the slides, the arrays were scanned using an Agilent G2505C scanner, and the acquired array images were analyzed with Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing was performed using the GeneSpring GX.

| Table 1 Clinical characteristics of patients with leukoplakia vs normal tissue used in gene microarray (n = 103) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age             | Gender          | Smoking         | Alcohol Drinking | GERD            |
|                 | Male            | Female          |                  |                 |                 |
| Normal          | 42.3 ± 5.7      | 97 (94.2%)      | 6 (5.8%)         | 45 (43.7%)      | 34 (33.0%)      | 6 (5.8%)        |
| Leukoplakia     | 45.8 ± 6.9      | 99 (96.1%)      | 4 (4.9%)         | 87 (84.5%)      | 72 (69.9%)      | 37 (35.9%)      |

GERD: Gastroesophageal Reflux Disease
v12.0 software package (Agilent Technologies). The microarray work was performed by KangChen Bio-tech, Shanghai, People’s Republic of China.

**Functional group analysis**
We used Gene Ontology analysis (GO: http://www.geneontology.org) and pathway analysis to determine the function and pathways of the differentially expressed mRNAs in vocal cord leukoplakia tissues compared to adjacent control vocal cord tissues. The P-value denotes the significance of GO Term enrichment in the differentially expressed mRNA list (\(P < 0.05\) was considered statistically significant). The pathway analyses for the differentially expressed mRNAs were performed based on the latest Kyoto Encyclopedia of Genes and Genomes (KEGG: http://www.genome.ad.jp/kegg/). This analysis allowed us to determine the biological pathways for which a significant enrichment of differentially expressed mRNAs existed (\(P < 0.05\) was considered statistically significant).

**Quantitative PCR**
Total RNA was extracted from frozen vocal cord leukoplakia tissues by using TRIzol reagent (Invitrogen) and then reverse-transcribed using an RT Reagent Kit (Thermo Scientific), according to the manufacturer’s instructions. LncRNAs expression in vocal cord leukoplakia tissues was measured by quantitative PCR by using SYBR Premix Ex Taq and an ABI 7000 instrument. Some candidate IncRNAs were validated by SYBRP PCR, these genes’ primers in the study for Q-PCR. Total RNA (2 mg) was transcribed to cDNA. PCR was performed in a total reaction volume of 20 μl, including 10 μl of SYBR Premix (2×), 2 μl of cDNA template, 1 μl of PCR forward primer (10 mM), 1 μl of PCR reverse primer (10 mM), and 6 μl of double-distilled water. The quantitative real-time PCR reaction included an initial denaturation step of 10 min at 95 °C; 40 cycles of 5 s at 95 °C, 30 s at 60 °C; and a final extension step of 5 min at 72 °C. All experiments were performed in triplicate, and all samples were normalized to GAPDH. The median in each triplicate was used to calculate relative IncRNAs concentrations (\(^\Delta\)Ct = Ct median IncRNA - Ct median GAPDH), and the fold changes in expression were calculated [16].

**Statistical methods**
All results are represented as mean ± standard deviation. Statistical analysis was performed for the comparison of two groups in the microarray, and analysis of variance for multiple comparisons was performed the Student’s t-test using SPSS software (Version 17.0 SPSS Inc.). A value of \(p < 0.05\) was considered statistically significant.

The fold change and the Student’s t-test were used to analyze the statistical significance of the microarray results. The false discovery rate (FDR) was calculated to correct the P-value. The threshold value used to designate differentially expressed IncRNAs and mRNAs was a fold change \(≥2.0\) or \(≤0.5\) (\(p < 0.05\)).

**Results**
**Overview of lncRNA profiles**
To study the potential biological functions of IncRNAs in vocal cord leukoplakia, we examined the IncRNA and mRNA expression profiles in human leukoplakia by microarray analysis (Figs. 1 and 2). In this study, authoritative data sources containing more than 30,586 IncRNAs were used to study the potential biological functions of IncRNA and mRNA expression profiles in vocal cord leukoplakia through microarray analysis. Our
results showed that there were 170 differentially expressed lncRNAs (fold change ≥2.0 or ≤0.5; *P* < 0.05) between vocal cord leukoplakia and normal vocal cord samples. Among these, 142 lncRNAs were found to be up-regulated in the vocal cord leukoplakia group compared to the normal vocal cord mucosal group, while 28 lncRNAs were down-regulated between these two groups (Table 2 shows the top 10 differentially expressed lncRNAs). Among these, XLOC_000605 was the most significantly up-regulated lncRNA and DLX6-AS1 was the most significantly down-regulated one.

**LncRNAs classification and subgroup analysis**

**Differentially expressed antisense lncRNAs and nearby coding genes**

Mammalian genomes encode numerous natural antisense transcripts. Functional validation studies indicate that antisense transcripts are not a uniform group of regulatory RNAs but instead belong to multiple categories with some common features. Recent evidence indicates that antisense transcripts are frequently functional and use diverse transcriptional and post-transcriptional gene regulatory mechanisms to carry out a wide variety of biological roles [17]. In this study, LOC100506801 was the only differentially expressed antisense lncRNA (fold change ≥2.0, *P* < 0.05) between vocal cord leukoplakia and normal vocal cord samples. It was significantly up-regulated as was its nearby gene, ECE19 (fold change = 1.70, *P* = 0.001).

**Differentially expressed enhancer-like lncRNAs and nearby coding genes**

Ørom UA et al. found an enhancer-like function for a set of lncRNAs in human cell lines. Depletion of these lncRNAs led to decreased expression of their neighboring protein-coding genes [18]. In this study, we identified the lncRNAs with enhancer-like lncRNA functions using GENCODE annotation. Our results reveal that AK057351 was the only differentially expressed enhancer-like lncRNA (fold change ≥2.0, *P* < 0.05) between vocal cord leukoplakia and normal vocal cord samples. It was up-regulated and its nearby gene was EFHA1. EFHA1 was itself up-regulated like the enhancer-like lncRNA (fold change =2.43, *P* = 0.03).

**Differentially expressed lincRNAs and associated coding gene**

Long intergenetic noncoding RNAs (lincRNAs) are transcribed from thousands of loci in mammalian genomes and might play widespread roles in gene regulation and other cellular processes [19]. In this study, we identified 3 differentially expressed lincRNAs and associated coding mRNAs (fold change ≥2.0, *P* < 0.05): XLOC_008001, XLOC_011989 and XLOC_007341. All of them were up-regulated as were their associated mRNAs, MSN (fold change =1.63, *P* = 0.01), RRAD

| LncRNAs                | Fold Change | LncRNAs        | Fold Change |
|------------------------|-------------|----------------|-------------|
| XLOC_000605            | 17.24       | DLX6-AS1       | 4.14        |
| RP11-18707.3           | 6.17        | KRT17P2        | 4.13        |
| XLOC_011401            | 5.31        | RP13-608F4.1   | 3.08        |
| SAC5-AS1               | 4.98        | L25629         | 2.90        |
| XLOC_011403            | 4.92        | CTD-2382E5.1   | 2.63        |
| FAM86FP                | 4.11        | RP11-351E7.1   | 2.58        |
| LOC100131138           | 3.96        | HRC2P2         | 2.49        |
| AC005152.2             | 3.86        | SAA3P          | 2.48        |
| AC0049203              | 3.82        | XLOC_006684    | 2.43        |
| XLOC_008001            | 3.78        | VNN2           | 2.36        |

Table 2 Top 10 differentially expressed lncRNAs in vocal cord leukoplakia tissue compared with adjacent non-tumorous tissue

up-regulated down-regulated

[Fig. 2 Heat map and hierarchical clustering of lncRNA profile comparison between the vocal cord leukoplakia and normal vocal cord samples. Red color indicates over expression and green color indicates low expression. Every column represents a tissue sample and every row represents an lncRNA probe. C represents leukoplakia tissues and N represents adjacent normal tissues]
(fold change = 2.69, \( P = 0.04 \)) and TPM2 (fold change = 1.68, \( P = 0.007 \)), respectively.

**Overview of mRNA profiles**

Ninety-nine mRNAs were found to be differentially expressed between vocal cord leukoplakia and normal vocal cord mucosa tissue (fold change \( \geq 2.0, P < 0.05 \)). Among these, 54 were up-regulated and 45 were down-regulated (Table 3 shows the top 10 differentially expressed mRNAs).

**GO analysis**

GO analysis is a functional analysis that associates differentially expressed mRNAs. The GO categories were derived from the Gene Ontology website (www.geneontology.org) and comprised of 3 structured networks: biological processes, cellular components and molecular function. According to the GO annotation tool, the genes corresponding to the down-regulated mRNAs included 455 genes involved in biological processes, 73 genes involved in cellular components and 60 genes involved in molecular functions. The genes corresponding to the up-regulated mRNAs included 109 genes involved in biological processes, 12 genes involved in cellular components, and 21 genes involved in molecular functions.

**Pathway analysis**

We performed the pathway analysis based on the latest Kyoto Encyclopedia of Genes and Genomes (KEGG) database. This analysis was used to determine the biological pathways associated with the most differentially expressed mRNAs in vocal cord leukoplakia. Our results identified 5 up-regulated pathways (including Primary immunodeficiency, Glioma, Melanoma, Bile secretion, Cell cycle signaling pathways) (Fig. 3) and 14 down-regulated pathways (including ECM-receptor interaction, focal adhesion, Regulation of actin cytoskeleton, Proteoglycans in cancer, TGF-beta signaling pathway, Cell adhesion molecules and PI3K-Akt signaling pathways) (Fig. 4).

**Real-time quantitative PCR validation**

Based on features of the differentially expressed lncRNAs such as fold difference, gene locus, and nearby encoding genes, a number of interesting candidate lncRNAs were selected for further analysis (including XLOC_000605, RP11-18707.3, XLOC_011403, XLOC-011401, SACS-AS1, FAM86FP, DLX6-AS1, KRT17P2). We verified the expression of these IncRNAs by real-time quantitative RT-PCR by using GAPDH as a reference gene and by calculating the \( 2^{-\Delta\Delta CT} \) values. The results showed that the microarray results for the selected IncRNAs were consistent with the results of RT-PCR (Fig. 5).

**Discussion**

In recent years, researchers have focused their attention on the analysis of protein-coding transcripts to characterize patterns and potential functional roles. The development of next-generation sequencing technology has led to the discovery of a new class of non-coding RNA transcripts, IncRNAs. Numerous investigations suggest that IncRNAs perform key regulatory functions in chromatin remodeling and gene expression in many biological processes, including X-chromosome inactivation, gene imprinting, and stem cell maintenance [20, 21]. Furthermore, IncRNAs are important factors in the control of gene expression in cancer [22], and IncRNAs such as HOTAIR have been shown to play a significant role in the development and progression of tumors [8]. It has also been demonstrated that IncRNAs are differentially expressed in normal cells and tumor cells. As IncRNAs constitute an important class of gene expression regulatory factors, their aberrant expression would inevitably lead to abnormal gene expression levels, which may result in tumorigenesis. Promoters bind to many transcription factors by mechanisms such as chromosomal
rearrangements and transfer elements [23]. However, the profile and the biological function of lncRNAs in vocal cord leukoplakia remain unknown.

Until now, there have been no reports describing the expression profiles of lncRNAs in vocal cord leukoplakia and there have been no studies on the association of lncRNA expression with the clinical characteristics and outcomes of in vocal cord leukoplakia. In this study, we analyzed the lncRNAs expression profiles in the tissues of vocal cord leukoplakia to uncover the potential role of lncRNAs in the pathogenesis of its tumorigenesis. High-throughput microarray techniques revealed a set of differentially expressed lncRNAs, including 142 that were up-regulated and 28 that were down-regulated in vocal cord leukoplakia tissue compared to normal vocal cord mucosa. Furthermore, we identified several subgroups of lncRNA, including antisense lncRNA, enhancer-like lncRNA, and lincRNA. Enhancers are classically defined as cis-acting DNA sequences that can increase the transcription of genes. They generally function independently of orientation and at various distances from their target promoter (or promoters) [24]. Ørom et al. also found some lncRNAs with enhancer-like functions in human cells [18]. In this study, we identified a significantly up-regulated enhancer-like lncRNA AK057351 and its associated gene EFHA1. Antisense lncRNAs are another subgroup of lncRNAs which can induce chromatin and DNA epigenetic changes, thus affecting the expression of sense mRNA. In this study, we identified an up-regulated antisense lncRNA LOC100506801 and its associated gene, ECE19. LincRNA are long non-coding sequences located between the protein-coding genes. More than 3500 lincRNAs have been reported in mammalian genome so far, which are involved in physiological processes through regulation of gene expression. Aberrant expression of lincRNAs has been found in both solid tumors and leukemia. The role of lincRNAs, however, remains unclear. In this study, we identified 3 significantly up-regulated lincRNAs and associated coding mRNAs. They were XLOC_000605, RP11-187O7.3, XLOC_011403, XLOC-011401, SACS-AS1, FAM86FP, DLX6-AS1, KRT17P2 determined to be differentially expressed in vocal cord leukoplakia samples compared with NT samples in three patients by microarray were validated by qPCR. The heights of the columns in the chart represent the log-transformed median fold changes (T/N) in expression across the three patients for each of the four lncRNAs validated. The validation results of the 8 lncRNAs indicated that the microarray data correlated well with the qPCR results.

To investigate the lncRNAs’ target gene function, GO analysis and KEGG pathway annotation were applied to the lncRNAs’ target gene pool. GO analysis revealed that the number of genes corresponding to down-regulated mRNAs was larger than that corresponding to up-

**Fig. 4** Pathway analysis of downregulated mRNAs in vocal cord leukoplakia. Fifteen downregulated pathways were identified, including ECM-receptor interaction, focal adhesion, Regulation of actin cytoskeleton, Proteoglycans in cancer, TGF-beta signaling pathway, Cell adhesion molecules and PI3K-Akt signaling pathways.

**Fig. 5** Comparison between gene chip data and qPCR result. XLOC_000605, RP11-187O7.3, XLOC_011403, XLOC-011401, SACS-AS1, FAM86FP, DLX6-AS1, KRT17P2 determined to be differentially expressed in vocal cord leukoplakia samples compared with NT samples in three patients by microarray were validated by qPCR. The heights of the columns in the chart represent the log-transformed median fold changes (T/N) in expression across the three patients for each of the four lncRNAs validated. The validation results of the 8 lncRNAs indicated that the microarray data correlated well with the qPCR results.
regulated mRNAs. KEGG annotation showed that there were 5 up-regulated pathways (including ethanol metabolism, viral carcinogenesis, RNA transduction, and cell cycle pathways) and 14 down-regulated pathways (including propionate metabolism and fatty acid metabolism pathways). These pathways might play important roles in vocal cord leukoplakia tumorigenesis. Further studies should be performed to investigate this hypothesis. 8 of the lncRNAs identified in the microarray analysis were confirmed by RT-PCR to be aberrantly expressed in vocal cord leukoplakia tissues. Among these lncRNAs, XLOC_000605 was the most significantly up-regulated, and DLX6-AS1 was the most significantly down-regulated. Little has been known about the function of these two lncRNAs until now. These findings may provide a potential strategy to distinguish between vocal cord leukoplakia tissue and normal vocal cord tissue. Our results suggest that these two lncRNAs might contribute to vocal cord leukoplakia tumorigenesis. Further studies of the biological function of XLOC_000605 and DLX6-AS1 will be required to confirm this potential association.

Conclusions
In conclusion, our study revealed a set of lncRNAs with differential expression in vocal cord leukoplakia compared with normal larynx mucous tissue, and also identified several subgroups of lncRNAs such as antisense lncRNAs, enhancer-like lncRNAs and lincRNAs. Moreover, we found that XLOC_000605 and DLX6-AS1 were significantly dysregulated and these two lncRNAs might contribute to vocal cord leukoplakia tumorigenesis. One limitation to this study is the small sample size, which may have been insufficient to detect every truly differentially expressed gene. In addition, we did not investigate the function of the differentially expressed genes which were identified. Further investigations directed at the lncRNAs and mRNAs identified above will be required to uncover their biological functions and their association with vocal cord leukoplakia tumorigenesis.

Abbreviations
GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; lincRNA: long intergenic noncoding RNA; lncRNA: long non-coding RNA; NT: nontumorous tissue

Acknowledgements
Not applicable.

Ethical approval and consent to participate
This study was approved by the Institutional Ethics Review Board of the First Affiliated Hospital of Wenzhou Medical University and informed consent was obtained for our study from all participating patients.

Funding
This study was supported by a grant number 2013C33241 from Public Technology Application Research Foundation from Department of Science and Technology of Zhejiang Province and Y20110090 from Wenzhou Municipal Science and Technology Bureau Foundation.

Availability of data and materials
Data is available upon request by contacting the corresponding author.

Authors’ contributions
PJ, LH, CJ, WX, JT and CX participated in the conceptualization and design of the study, analysis and interpretation of data, drafting and/or revising the manuscript, and have approved the manuscript as submitted.

Authors’ information
All authors are affiliated with the First Affiliated Hospital of Wenzhou Medical University.

Consent for publication
All authors have agreed to publish this article in Journal of Otolaryngology-Head & Neck Surgery.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Otolaryngology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. 2Institute of Translation Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.

Received: 23 March 2017 Accepted: 29 January 2018
Published online: 12 February 2018

References
1. Isenberg JS, Crozier DL, Dailey SH. Institutional and comprehensive review of laryngeal leukoplakia. Ann Otol Rhinol Laryngol. 2008;117(1):74–9.
2. Singh I, Gupta D, Yadav S. Leukoplakia of larynx: a review article. J Laryngol Voice. 2014;4:39–44.
3. Jeonnon J, Soames J, Aston V, Stafford FW, Wilson JA. Molecular markers in dysplasia of the larynx: expression of cyclin-dependent kinase inhibitors p21, p27 and p53 tumour suppressor gene in predicting cancer risk. Clin Otolaryngol Allied Sci. 2004;29:698–704.
4. Ioachim E, Peschos D, Goussa A, Mitrani E, Charalabopoulos K, Michael M, et al. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features. J Exp Clin Cancer Res. 2004;23:277–83.
5. Forastiere A, Koch W, Triotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890–900.
6. Bartlett RS, Heckman WW, Isenberg J, Thibeault SL, Dailey SH. Genetic characterization of vocal fold lesions: leukoplakia and carcinoma. Laryngoscope. 2012;122(2):336–42.
7. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.
8. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.
9. Shen Z, Li Q, Deng H, Lu D, Song H, Guo J. Long non-coding RNA profiling in laryngeal squamous cell carcinoma and its clinical significance: potential biomarkers for LSCC. PLoS One. 2014;9(9):e108237.
10. Feng L, Wang R, Lian M, Ma H, He N, Liu H, et al. Integrated analysis of long noncoding RNA and mRNA expression profile in advanced laryngeal Squamous cell carcinoma. PLoS One. 2016;11(12):e0169232.
11. Guan GF, Zhang DJ, Wen LJ, Xin D, Liu Y, Yu DJ, et al. Overexpression of IncRNA H19/miR-675 promotes tumorigenesis in head and neck squamous cell carcinoma. Int J Med Sci. 2016;13(12):914–22.
12. Wu T, Qu L, He G, Tian L, Li L, Zhou H, et al. Regulation of laryngeal squamous cell cancer progression by the IncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget. 2016;7(10):11553–66.
13. Zhang C, Gao W, Wen S, Wu Y, Fu R, Zhao D, et al. Potential key molecular correlations in laryngeal squamous cell carcinoma revealed by integrated analysis of mRNA, miRNA and lncRNA microarray profiles. Neoplasma. 2016;63(6):888–900.

14. Wang P, Wu T, Zhou H, Jin Q, He G, Yu H, et al. Long noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6 pathway. J Exp Clin Cancer Res. 2016;35:22.

15. Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, et al. Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One. 2014;9(8):e104044.

16. Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 2012;22(5):806–21.

17. Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 2009;10(9):637–43.

18. Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010;143(1):46–58.

19. Ullitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46.

20. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.

21. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904–14.

22. Khachane AN, Harrison PM. Mining mammalian transcript data for functional long non-coding RNAs. PLoS One. 2010;5(4):e10316.

23. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38(4):431–40.

24. Pennacchio LA, Bickmore W, Dean A, Nobrega MA, Bejerano G. Enhancers: five essential questions. Nat Rev Genet. 2013;14(4):288–95.